Q1 2026 Results: Revenue, EBITDA and EPS Growth
Medpace Holdings, Inc. (MEDP) reported a quarter that looked strong on the income statement but less reassuring on forward demand indicators. Revenue in Q1 2026 rose 26.5% year over year to $706.6 million from $558.6 million. EBITDA increased 25.9% to $149.4 million from $118.6 million, while EBITDA margin was 21.1% compared with 21.2% a year earlier. GAAP diluted EPS rose to $4.28 from $3.67.
By those measures alone, the quarter was solid. Revenue growth remained strong, profitability held up, and earnings per share improved. That explains why the quarter cannot be described as an operational miss in a simple sense.
The issue is that Medpace was not being judged only on what it converted into revenue this quarter. Investors were also focused on what the bookings and backlog figures implied about the next several quarters.
Why the 0.88x Book-to-Bill Ratio Drove the Reaction
Net new business awards were $618.4 million in Q1 2026, up from $500.0 million a year earlier. But because revenue ran ahead of awards, Medpace’s net book-to-bill ratio was 0.88x. That is the figure that appears to have driven the stock’s sharp reaction.
A book-to-bill ratio below 1.0 does not mean demand has collapsed. It does mean the company added new awards more slowly than it recognized revenue during the quarter. For a contract research organization, that can raise questions about the pace of future revenue replenishment.
This is why a quarter with strong revenue and EPS can still create investor concern. The market often gives more weight to bookings quality and backlog trajectory than to one period of recognized revenue, especially when expectations for future growth are already high. In Medpace’s case, the debate is less about whether the company executed well in Q1 and more about whether the next few quarters will show stronger replenishment of future work. That is a more demanding standard, but it is also a common one for companies that trade on confidence in pipeline durability.
Backlog, Guidance and What Investors Are Watching Next
Ending backlog was $2,929.2 million at the end of the quarter, up 3.2% from $2,838.6 million a year earlier. That is still growth, but it is not the kind of backlog expansion that would fully offset concern around a sub-1.0 book-to-bill ratio. The backlog conversion rate was 23.3%, which helps explain why revenue remained strong in the current quarter even as investors focused more on future demand replenishment.
Management kept full-year 2026 guidance unchanged. That is an important stabilizing point. It suggests Medpace does not see Q1 as enough to warrant a reset in its full-year outlook. Even so, unchanged guidance does not automatically remove concern when the market is focused on whether bookings can reaccelerate.
Another way to read the quarter is that Medpace converted backlog efficiently in Q1, but the market wanted clearer evidence that new awards were rebuilding the pipeline at a similar pace. That distinction is why the quarter can look strong in reported revenue and still feel cautious from a forward-looking perspective. For now, Medpace appears operationally solid, but the burden of proof has shifted toward future order flow rather than current-quarter margin performance.
The practical takeaway is that Medpace still looks healthy on execution, but investors now have a more obvious reason to watch new awards and backlog growth more closely than the headline income statement.
Key Signals for Investors
- Q1 execution was strong, with revenue up 26.5% to $706.6 million, EBITDA up 25.9% to $149.4 million, and GAAP EPS rising to $4.28.
- The main issue was forward demand quality, as net new business awards of $618.4 million translated into a 0.88x net book-to-bill ratio.
- Unchanged full-year 2026 guidance helps, but investors will likely stay focused on whether backlog growth and bookings momentum improve from here.